Advertisement
NKTX vs RNAC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTX is a Hold and RNAC is a Hold.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RNAC's RSI Oscillator recovers from oversold territory
The RSI Indicator for RNAC moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 38 of the 43 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RNAC as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 50 cases where RNAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
RNAC moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for RNAC moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
RNAC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RNAC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.819) is normal, around the industry mean (3.498). P/E Ratio (-1.303) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX | RNAC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 84 | 70 | |
P/E GROWTH RATING 1..100 | 14 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RNAC's Valuation (27) in the Biotechnology industry is in the same range as NKTX (37) in the null industry. This means that RNAC’s stock grew similarly to NKTX’s over the last 12 months.
RNAC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NKTX (100) in the null industry. This means that RNAC’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's SMR Rating (97) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to RNAC’s over the last 12 months.
RNAC's Price Growth Rating (70) in the Biotechnology industry is in the same range as NKTX (84) in the null industry. This means that RNAC’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (14) in the null industry is in the same range as RNAC (34) in the Biotechnology industry. This means that NKTX’s stock grew similarly to RNAC’s over the last 12 months.
| NKTX | RNAC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 84% | 8 days ago 83% |
| Declines ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NKTX’s FA Score shows that 1 FA rating(s) are green while RNAC’s FA Score has 1 green FA rating(s).
- NKTX’s FA Score: 1 green, 4 red.
- RNAC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NKTX’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).
- NKTX’s TA Score: 5 bullish, 4 bearish.
- RNAC’s TA Score: 4 bullish, 6 bearish.
Price Growth
NKTX (@Biotechnology) experienced а -11.76% price change this week, while RNAC (@Biotechnology) price change was +7.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
NKTX is expected to report earnings on Mar 25, 2027.
RNAC is expected to report earnings on Mar 17, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -15.09% | ||
| CRSP - NKTX | 49% Loosely correlated | -9.77% | ||
| EDIT - NKTX | 47% Loosely correlated | -8.91% | ||
| PROK - NKTX | 45% Loosely correlated | -3.48% | ||
| VIR - NKTX | 45% Loosely correlated | -3.63% | ||
| RNAC - NKTX | 45% Loosely correlated | -1.85% | ||
More | ||||
RNAC and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To RNAC | 1D Price Change % | ||
|---|---|---|---|---|
| RNAC | 100% | -1.85% | ||
| TAOX - RNAC | 91% Closely correlated | -5.15% | ||
| PALI - RNAC | 81% Closely correlated | -5.04% | ||
| NKTX - RNAC | 45% Loosely correlated | -15.09% | ||
| EDIT - RNAC | 44% Loosely correlated | -8.91% | ||
| LXEO - RNAC | 42% Loosely correlated | -2.55% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ATTR | 96.21 | -0.01 | -0.01% |
| Arin Tactical Tail Risk ETF | |||
| FIDU | 89.61 | -0.12 | -0.13% |
| Fidelity MSCI Industrial Index ETF (FIDU) | |||
| FIDI | 28.75 | -0.13 | -0.45% |
| Fidelity International High Dividend ETF (FIDI) | |||
| HOMZ | 43.80 | -0.83 | -1.86% |
| Hoya Capital Housing ETF (HOMZ) | |||
| SOUX | 3.14 | -0.31 | -9.03% |
| Defiance Daily Target 2X Long SOUN ETF (SOUX) | |||